表紙
市場調查報告書

亞太地區的藥物開發市場規模,佔有率,趨勢分析:各手法(公司內部,外包),各流程階段(DMPK,安全性評估),各治療領域,市場區隔預測(2019∼2026年)

Asia Pacific Drug Development Market Size, Share & Trends Analysis Report By Mode (In house, Outsourced), By Process Step (DMPK, Safety Assessment), By Therapeutic Area, And Segment Forecasts, 2019 - 2026

出版商 Grand View Research, Inc. 商品編碼 906567
出版日期 內容資訊 英文 240 Pages
商品交期: 2-3個工作天內
價格
Back to Top
亞太地區的藥物開發市場規模,佔有率,趨勢分析:各手法(公司內部,外包),各流程階段(DMPK,安全性評估),各治療領域,市場區隔預測(2019∼2026年) Asia Pacific Drug Development Market Size, Share & Trends Analysis Report By Mode (In house, Outsourced), By Process Step (DMPK, Safety Assessment), By Therapeutic Area, And Segment Forecasts, 2019 - 2026
出版日期: 2019年07月09日內容資訊: 英文 240 Pages
簡介

亞太地區的藥物開發市場規模預測今後將以年複合成長率6.54%擴大,至2026年達到624億6,000萬美元的規模。大型製藥公司面臨研究費的增加和減收等課題,使得亞洲的藥物開發部門大幅擴大。

本報告提供亞太地區的藥物開發市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業簡介等相關資訊彙整。

第1章 摘要整理

第2章 調查方法

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透及成長預測製圖
  • SWOT分析
  • 產業分析:波特分析

第4章 各手法預測與趨勢分析

  • 趨勢分析
  • 公司內部
  • 外包

第5章 各流程階段預測與趨勢分析

  • 趨勢分析
  • 流程研究開發
  • 製作
  • 分析、安全性實驗
  • 藥物代謝、藥物動力學
  • 安全性評估(毒理學)
  • 法規支援
  • 包裝

第6章 各治療領域預測與趨勢分析

  • 趨勢分析
  • 腫瘤
  • 發炎、免疫
  • 心臟
  • 神經科學
  • 其他

第7章 各國預測與趨勢分析

  • 各國市場佔有率
  • 印度
  • 中國
  • 新加坡
  • 日本
  • 韓國
  • 印尼
  • 澳洲
  • 馬來西亞
  • 越南

第8章 競爭環境

  • 策略性架構
  • 市場進入分類
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-3-68038-222-8

The Asia Pacific drug development market is expected to reach USD 62.46 billion by 2026 and is projected to expand at a CAGR of 6.54%, according to a new report by Grand View Research, Inc. Challenges pertaining to the escalating research costs and shrinking revenue faced by major pharma companies have led to the significant expansion of Asian drug development sector. A rapidly expanding healthcare infrastructure, low operating costs, and a growing patient population have contributed to the recognition of Asian countries as an ideal site for low-cost drug development.

Furthermore, the growing acceptance of clinical trial data generated in Asia by Western drug regulators, including the EMA and U.S. FDA, is one of the key market drivers. This is primarily because of the increasing similarities of Asian disease demographics to that of the Western nations.

Various government policies have been formulated to promote implementation of digital and advanced analytics, such as artificial intelligence, in the region. Moreover, the pharma companies are collaborating with AI-based companies to leverage algorithms and cloud computing to transform their drug development process.

The contract research organizations are experiencing increasing levels of interest in Asian countries from their U.S. -based client base. This is a testament to the lucrative growth of Asia Pacific market, driving its growth in the coming years.

Further key findings from the report suggest:

  • Outsourced mode of pharmaceutical development led the market and is expected to maintain its dominance throughout the forecast period, due to the fact that the companies are investing or redirecting their significant investments from already existing R&D centers in Europe and U.S. to emerging centers in Asia
  • Analytical & stability studies captured the largest revenue share in the market, due to the high usage of advanced and relative expensive technologies such as Electron Paramagnetic Resonance (EPR) spectroscopy
  • Oncology is estimated to be the highest revenue generating segment, due to the presence of a substantial number of cancer targeting therapeutics in clinical development phase. This segment is expected to maintain a fast CAGR during the forecast period owing to wide acceptance of personalized therapy in cancer treatment
  • Strong government support for innovation and large and diverse domestic pharma industry of China has led to the dominance of China over other countries in the Asia Pacific drug development market
  • Furthermore, the launch of several start-ups in India is expected to serve as a significant source of revenue to the Indian pharmaceutical industry
  • Some key contract service providers operating in the Asia Pacific drug development market are Eurofins Advinus; Covance Inc.; Celerion; and Parexel International Corporation. With the rising trend of outsourcing pharmaceutical manufacturing, these CROs are expected to witness great organic revenue growth
  • In house global pharmaceutical manufacturers such as Pfizer and AstraZeneca are also striving to gain competitive ground in the Asian market

Table of content

Chapter 1 Executive Summary

  • 1.1 Market Snapshot

Chapter 2 Research Methodology

  • 2.1 Information Procurement
  • 2.2 Information or Data Analysis
  • 2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation & Scope
    • 3.1.1 Market driver analysis
      • 3.1.1.1 Rising pharma R&D outsourcing
      • 3.1.1.2 Growing accessibility to Artificial Intelligence (AI) for pharmaceutical research
      • 3.1.1.3 Expansion in the global drug developer in Asian market
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Different approval timelines
      • 3.1.2.1 Presence of well-established players in western market
  • 3.2 Penetration & Growth Prospect Mapping For Process Step Scope, 2018
  • 3.3 Asia Pacific Drug Development Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Asia Pacific Drug Development Market Categorization: Mode Estimates & Trend Analysis

  • 4.1 Asia Pacific Drug Development Market: Mode Movement Analysis
  • 4.2 In house
    • 4.2.1 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
  • 4.3 Outsourced
    • 4.3.1 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)

Chapter 5 Asia Pacific Drug Development Market Categorization: Process Step Estimates & Trend Analysis

  • 5.1 Asia Pacific Drug Development Market: Process Step Movement Analysis
  • 5.2 Process Research Development
    • 5.2.1 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
  • 5.3 Formulation
    • 5.3.1 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
  • 5.4 Analytical & stability studies
    • 5.4.1 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
  • 5.5 Drug Metabolism and Pharmacokinetics (DMPK)
    • 5.5.1 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
  • 5.6 Safety Assessment (Toxicology)
    • 5.6.1 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
  • 5.7 Regulatory Compliance
    • 5.7.1 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
  • 5.8 Packaging
    • 5.8.1 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)

Chapter 6 Asia Pacific Drug Development Market Categorization: Therapeutic Area Estimates & Trend Analysis

  • 6.1 Asia Pacific Drug Development Market: Therapeutic Area Movement Analysis
  • 6.2 Oncology
    • 6.2.1 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
  • 6.3 Inflammation & Immunology
    • 6.3.1 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
  • 6.4 Cardiology
    • 6.4.1 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
  • 6.5 Neuroscience
    • 6.5.1 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
  • 6.6 Others
    • 6.6.1 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)

Chapter 7 Asia Pacific Drug Development Market Categorization: Country Estimates & Trend Analysis, by Mode, Process Step, & Therapeutic Area

  • 7.1 Asia Pacific Drug Development Market Share, By Country, 2018 & 2026
  • 7.2 India
    • 7.2.1 India drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.2.2 India drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.2.3 India drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.3 China
    • 7.3.1 China drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.3.2 China drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.3.3 China drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.4 Singapore
    • 7.4.1 Singapore drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.4.2 Singapore drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.4.3 Singapore drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.5 Japan
    • 7.5.1 Japan drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.5.2 Japan drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.5.3 Japan drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.6 South Korea
    • 7.6.1 South Korea drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.6.2 South Korea drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.6.3 South Korea drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.7 Indonesia
    • 7.7.1 Indonesia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.7.2 Indonesia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.7.3 Indonesia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.8 Australia
    • 7.8.1 Australia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.8.2 Australia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.8.3 Australia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.9 Malaysia
    • 7.9.1 Malaysia drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.9.2 Malaysia drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.9.3 Malaysia drug development market, by therapuetic area, 2015 - 2026 (USD Million)
  • 7.10 Vietnam
    • 7.10.1 Vietnam drug development market, by mode, 2015 - 2026 (USD Million)
    • 7.10.2 Vietnam drug development market, by process step, 2015 - 2026 (USD Million)
    • 7.10.3 Vietnam drug development market, by therapuetic area, 2015 - 2026 (USD Million)

Chapter 8 Asia Pacific Drug Development Market: Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participant Categorization
  • 8.3 Company Profiles
    • 8.3.1 Samsung BioLogics
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 WuXi Biologics
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Celltrion Inc.
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 PT Kalbe Farma Tbk
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 Eurofins Advinus
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 Covance Inc.
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 Celerion
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Parexel International Corporation
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 GVK Biosciences Private Limited
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Vifor Pharma Asia Pacific Pte. Ltd
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Financial performance
      • 8.3.10.4 Product benchmarking

List of Tables

  • TABLE 1 ASEAN guidelines on stability study and shelf-life of traditional medicines
  • TABLE 2 Regulatory bodies governing drug development in Asia Pacific
  • TABLE 3 India drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 4 India drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 5 India drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 6 China drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 7 China drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 8 China drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 9 Singapore drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 10 Singapore drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 11 Singapore drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 12 Japan drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 13 Japan drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 14 Japan drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 15 South Korea drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 16 South Korea drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 17 South Korea drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 18 Indonesia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 19 Indonesia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 20 Indonesia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 21 Australia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 22 Australia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 23 Australia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 24 Malaysia drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 25 Malaysia drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 26 Malaysia drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)
  • TABLE 27 Vietnam drug development market estimates & forecasts, by mode, 2015 - 2026 (USD Million)
  • TABLE 28 Vietnam drug development market estimates & forecasts, by process step, 2015 - 2026 (USD Million)
  • TABLE 29 Vietnam drug development market estimates & forecasts, by therapeutic area, 2015 - 2026 (USD Million)

List of Figures

  • FIG. 1 Market snapshot
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value chain based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 Penetration & growth prospect mapping for Process Step Scope, 2018
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Asia Pacific drug development market: Mode outlook key takeaways
  • FIG. 16 Asia Pacific drug development market: Mode movement analysis
  • FIG. 17 Asia pacific in house drug development market, 2015 - 2026 (USD Million)
  • FIG. 18 Asia pacific outsourced drug development market, 2015 - 2026 (USD Million)
  • FIG. 19 Asia Pacific drug development market: Process step outlook key takeaways
  • FIG. 20 Asia Pacific drug development market: Process step movement analysis
  • FIG. 21 Asia pacific drug development market for process research development, 2015 - 2026 (USD Million)
  • FIG. 22 Asia pacific drug development market for formulation step, 2015 - 2026 (USD Million)
  • FIG. 23 Asia pacific drug development market for analytical & stability studies, 2015 - 2026 (USD Million)
  • FIG. 24 Asia pacific drug development market for Drug Metabolism and Pharmacokinetics (DMPK), 2015 - 2026 (USD Million)
  • FIG. 25 Toxicology studies during drug development
  • FIG. 26 Asia pacific drug development market for safety assessment (Toxicology), 2015 - 2026 (USD Million)
  • FIG. 27 Asia pacific drug development market for regulatory compliance, 2015 - 2026 (USD Million)
  • FIG. 28 Asia Pacific drug development market for packaging, 2015 - 2026 (USD Million)
  • FIG. 29 Asia Pacific drug development market: Therapeutic area outlook key takeaways
  • FIG. 30 Asia Pacific drug development market: Therapeutic area movement analysis
  • FIG. 31 Asia Pacific drug development market for oncology, 2015 - 2026 (USD Million)
  • FIG. 32 Asia Pacific drug development market for inflammation & immunology, 2015 - 2026 (USD Million)
  • FIG. 33 Asia Pacific drug development market for cardiology, 2015 - 2026 (USD Million)
  • FIG. 34 Asia Pacific drug development market for neuroscience, 2015 - 2026 (USD Million)
  • FIG. 35 Asia Pacific drug development market for other therapeutic area, 2015 - 2026 (USD Million)
  • FIG. 36 Regional market place: Key takeaway
  • FIG. 37 Asia Pacific drug development market: Country outlook, 2018 & 2026
  • FIG. 38 India drug development market, 2015 - 2026 (USD Million)
  • FIG. 39 India drug development market, 2015 - 2026 (USD Million)
  • FIG. 40 Singapore drug development market, 2015 - 2026 (USD Million)
  • FIG. 41 Japan drug development market, 2015 - 2026 (USD Million)
  • FIG. 42 South Korea drug development market, 2015 - 2026 (USD Million)
  • FIG. 43 Indonesia drug development market, 2015 - 2026 (USD Million)
  • FIG. 44 Australia drug development market, 2015 - 2026 (USD Million)
  • FIG. 45 Malaysia drug development market, 2015 - 2026 (USD Million)
  • FIG. 46 Vietnam drug development market, 2015 - 2026 (USD Million)
  • FIG. 47 Strategy framework
  • FIG. 48 Market participant categorization
Back to Top